Importantly, CRISPR depletion of COX4I1 delayed leukemia onset in recipient mice (Figure 2G), providing proof‐of‐concept evidence of targeting COX4I1 in vivo to disrupt the progression of human AML. This evidence concerns the gene COX4I1 and acute myeloid leukemia.